Product overview

Name Captopril
Alternative names CAP
Purity >98%
Description ACE and LTA4 hydrolase inhibitor
Write Your Own Review
You're reviewing:Captopril
Rate this item:

Biological Data

Biological description

Angiotensin-converting enzyme (ACE) inhibitor (IC50 = 0.022µM) which also inhibits LTA4 hydrolase in a reversible and competitive manner.

Shows antihypertensive and vasodilatory effects

Orally active.

Recently studied as part of COVID-19 compound repurposing.

Solubility & Handling

Storage instructions +4°C
Solubility overview Soluble in water (100mM) and in DMSO (100mM)
Handling In aqueous solution, Captopril undergoes a free radical dimerisation to form captopril disulfide. To delay oxidation, use a lower pH, degas solution, minimize headspace, increase the concentration or incorporate a chelating agent or antioxidant.
Important This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use



More Info


More Info

Chemical Data

Purity >98%
Chemical name 1-[(2S)-3-Mercapto-2-methyl-1-oxopropyl]-L-proline
Molecular Weight 217.29
Chemical structure Captopril [62571-86-2] Chemical Structure
Molecular Formula C9H15NO3S
CAS Number 62571-86-2
PubChem identifier 44093
InChi InChI=1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1
MDL number MFCD00168073

References for Captopril

References are publications that support the biological activity of the product
  • A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

    Gordon et al (2020) Nature : doi: 10.1038/s41586-020-2286-9.
  • Effects of early captopril treatment and its removal on plasma angiotensin converting enzyme (ACE) activity and arginine vasopressin in hypertensive rats (SHR) and normotensive rats (WKY)

    Zhang et al (1996) Clin Exp Hypertens 18(2) : 201-26
  • Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure

    Brogden et al (1988) Drugs. 36(5) : 540-600

3 Item(s)